Sort by
Items per page

Send to

Choose Destination

Best matches for Dropulić B[au]:

Search results

Items: 44


A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy.

Bari R, Granzin M, Tsang KS, Roy A, Krueger W, Orentas R, Pfeifer R, Moeker N, Verhoeyen E, Dropulic B, Leung W.

Front Immunol. 2019 Aug 22;10:2001. doi: 10.3389/fimmu.2019.02001. eCollection 2019.


Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model.

Anthony-Gonda K, Bardhi A, Ray A, Flerin N, Li M, Chen W, Ochsenbauer C, Kappes JC, Krueger W, Worden A, Schneider D, Zhu Z, Orentas R, Dimitrov DS, Goldstein H, Dropulić B.

Sci Transl Med. 2019 Aug 7;11(504). pii: eaav5685. doi: 10.1126/scitranslmed.aav5685.


A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia.

Schneider D, Xiong Y, Hu P, Wu D, Chen W, Ying T, Zhu Z, Dimitrov DS, Dropulic B, Orentas RJ.

Front Oncol. 2018 Nov 22;8:539. doi: 10.3389/fonc.2018.00539. eCollection 2018.


Stable Transcriptional Repression and Parasitism of HIV-1.

Shrivastava S, Charlins P, Ackley A, Embree H, Dropulic B, Akkina R, Weinberg MS, Morris KV.

Mol Ther Nucleic Acids. 2018 Sep 7;12:12-18. doi: 10.1016/j.omtn.2018.04.011. Epub 2018 May 1.


Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.

Zhu F, Shah N, Xu H, Schneider D, Orentas R, Dropulic B, Hari P, Keever-Taylor CA.

Cytotherapy. 2018 Mar;20(3):394-406. doi: 10.1016/j.jcyt.2017.09.005. Epub 2017 Dec 26.


Correction to: Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.

Moore T, Wagner CR, Scurti GM, Hutchens KA, Godellas C, Clark AL, Kolawole EM, Hellman LM, Singh NK, Huyke FA, Wang SY, Calabrese KM, Embree HD, Orentas R, Shirai K, Dellacecca E, Garrett-Mayer E, Li M, Eby JM, Stiff PJ, Evavold BD, Baker BM, Le Poole IC, Dropulic B, Clark JI, Nishimura MI.

Cancer Immunol Immunother. 2018 Feb;67(2):327. doi: 10.1007/s00262-017-2102-z.


CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.

Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, Shalabi H, Fountaine TJ, Shern JF, Majzner RG, Stroncek DF, Sabatino M, Feng Y, Dimitrov DS, Zhang L, Nguyen S, Qin H, Dropulic B, Lee DW, Mackall CL.

Nat Med. 2018 Jan;24(1):20-28. doi: 10.1038/nm.4441. Epub 2017 Nov 20.


Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.

Moore T, Wagner CR, Scurti GM, Hutchens KA, Godellas C, Clark AL, Kolawole EM, Hellman LM, Singh NK, Huyke FA, Wang SY, Calabrese KM, Embree HD, Orentas R, Shirai K, Dellacecca E, Garrett-Mayer E, Li M, Eby JM, Stiff PJ, Evavold BD, Baker BM, Le Poole IC, Dropulic B, Clark JI, Nishimura MI.

Cancer Immunol Immunother. 2018 Feb;67(2):311-325. doi: 10.1007/s00262-017-2073-0. Epub 2017 Oct 20. Erratum in: Cancer Immunol Immunother. 2017 Dec 20;:.


A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.

Schneider D, Xiong Y, Wu D, Nӧlle V, Schmitz S, Haso W, Kaiser A, Dropulic B, Orentas RJ.

J Immunother Cancer. 2017 May 16;5:42. doi: 10.1186/s40425-017-0246-1. eCollection 2017.


Reference Standards for Gene and Cell Therapy Products.

Dropulić B.

Mol Ther. 2017 Jun 7;25(6):1259-1260. doi: 10.1016/j.ymthe.2017.05.002. Epub 2017 May 11. No abstract available.


Towards a commercial process for the manufacture of genetically modified T cells for therapy.

Kaiser AD, Assenmacher M, Schröder B, Meyer M, Orentas R, Bethke U, Dropulic B.

Cancer Gene Ther. 2015 Mar;22(2):72-8. doi: 10.1038/cgt.2014.78. Epub 2015 Jan 23. Review.


Rapid generation of stable cell lines expressing high levels of erythropoietin, factor VIII, and an antihuman CD20 antibody using lentiviral vectors.

Baranyi L, Doering CB, Denning G, Gautney RE, Harris KT, Spencer HT, Roy A, Zayed H, Dropulic B.

Hum Gene Ther Methods. 2013 Aug;24(4):214-27. doi: 10.1089/hgtb.2013.002.


Harnessing autophagy for cell fate control gene therapy.

Felizardo TC, Foley J, Steed K, Dropulic B, Amarnath S, Medin JA, Fowler DH.

Autophagy. 2013 Jul;9(7):1069-79. doi: 10.4161/auto.24639. Epub 2013 Apr 17.


Lentiviral vector-mediated genetic modification of cell substrates for the manufacture of proteins and other biologics.

Baranyi L, Roy A, Embree HD, Dropulic B.

PDA J Pharm Sci Technol. 2010 Sep-Oct;64(5):379-85.


Lentiviral vectors: their molecular design, safety, and use in laboratory and preclinical research.

Dropulić B.

Hum Gene Ther. 2011 Jun;22(6):649-57. doi: 10.1089/hum.2011.058. Epub 2011 May 19. Review.


Lentiviral vector platform for production of bioengineered recombinant coagulation factor VIII.

Spencer HT, Denning G, Gautney RE, Dropulic B, Roy AJ, Baranyi L, Gangadharan B, Parker ET, Lollar P, Doering CB.

Mol Ther. 2011 Feb;19(2):302-9. doi: 10.1038/mt.2010.239. Epub 2010 Nov 16.


Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection.

Kimpel J, Braun SE, Qiu G, Wong FE, Conolle M, Schmitz JE, Brendel C, Humeau LM, Dropulic B, Rossi JJ, Berger A, von Laer D, Johnson RP.

PLoS One. 2010 Aug 23;5(8):e12357. doi: 10.1371/journal.pone.0012357.


Potent induction of B- and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection.

Loisel-Meyer S, Felizardo T, Mariotti J, Mossoba ME, Foley JE, Kammerer R, Mizue N, Keefe R, McCart JA, Zimmermann W, Dropulic B, Fowler DH, Medin JA.

Mol Cancer Ther. 2009 Mar;8(3):692-702. doi: 10.1158/1535-7163.MCT-08-0769. Epub 2009 Mar 10.


Potent inhibition of simian immunodeficiency virus (SIV) replication by an SIV-based lentiviral vector expressing antisense Env.

Braun SE, Lu XV, Wong FE, Connole M, Qiu G, Chen Z, Slepushkina T, Slepushkin V, Humeau LM, Dropulic B, Johnson RP.

Hum Gene Ther. 2007 Jul;18(7):653-64.


Gene transfer in humans using a conditionally replicating lentiviral vector.

Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, Lu X, Binder GK, Slepushkin V, Lemiale F, Mascola JR, Bushman FD, Dropulic B, June CH.

Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17372-7. Epub 2006 Nov 7.


Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells.

Braun SE, Wong FE, Connole M, Qiu G, Lee L, Gillis J, Lu X, Humeau L, Slepushkin V, Binder GK, Dropulic B, Johnson RP.

Mol Ther. 2005 Dec;12(6):1157-67. Epub 2005 Sep 15.


Novel lentiviral vectors for human gene therapy.

Dropulic B.

Expert Opin Investig Drugs. 1998 Jun;7(6):997-1001.


Current status of gene therapy strategies to treat HIV/AIDS.

Strayer DS, Akkina R, Bunnell BA, Dropulic B, Planelles V, Pomerantz RJ, Rossi JJ, Zaia JA.

Mol Ther. 2005 Jun;11(6):823-42. Review.


Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector.

Manilla P, Rebello T, Afable C, Lu X, Slepushkin V, Humeau LM, Schonely K, Ni Y, Binder GK, Levine BL, MacGregor RR, June CH, Dropulic B.

Hum Gene Ther. 2005 Jan;16(1):17-25. Review. Erratum in: Hum Gene Ther. 2005 Feb;16(2):279. Hum Gene Ther. 2006 Feb;17(2):252.


Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.

Ni Y, Sun S, Oparaocha I, Humeau L, Davis B, Cohen R, Binder G, Chang YN, Slepushkin V, Dropulic B.

J Gene Med. 2005 Jun;7(6):818-34. Erratum in: J Gene Med. 2005 Jun;7(6):835.


Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol.

Lu X, Humeau L, Slepushkin V, Binder G, Yu Q, Slepushkina T, Chen Z, Merling R, Davis B, Chang YN, Dropulic B.

J Gene Med. 2004 Sep;6(9):963-73.


Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load.

Humeau LM, Binder GK, Lu X, Slepushkin V, Merling R, Echeagaray P, Pereira M, Slepushkina T, Barnett S, Dropulic LK, Carroll R, Levine BL, June CH, Dropulic B.

Mol Ther. 2004 Jun;9(6):902-13.


ABC transporter inhibitors that are substrates enhance lentiviral vector transduction into primitive hematopoietic progenitor cells.

Davis BM, Humeau L, Slepushkin V, Binder G, Korshalla L, Ni Y, Ogunjimi EO, Chang LF, Lu X, Dropulic B.

Blood. 2004 Jul 15;104(2):364-73. Epub 2004 Apr 1.


Lentivirus in the clinic.

Dropulic B.

Mol Ther. 2001 Dec;4(6):511-2. No abstract available.


A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread.

Dropulić B, Hĕrmánková M, Pitha PM.

Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11103-8.


Locus-Control-Region-Coupled Beta (S)(Antilles)- and Alpha(2)-Hemoglobin Genes Select for High Alpha(2)-Hemoglobin Expression in Adult Transgenic Mice.

Shafer FE, Dropulic B, Ely C, Schaefer CA, Freas D, Witkowska HE, Schechter AN, Noguchi CT, Dewey M, Karlsson S.

J Biomed Sci. 1994 Jun;1(3):147-153.


Activation and inactivation of gene expression using RNA sequences.

Dropulic B, Smith SM, Jeang KT.

Adv Pharmacol. 1994;30:247-70. Review. No abstract available.


Effects of integration and replication on transcription of the HIV-1 long terminal repeat.

Jeang KT, Berkhout B, Dropulic B.

J Biol Chem. 1993 Nov 25;268(33):24940-9.


A method to increase the cumulative cleavage efficiency of ribozymes: thermal cycling.

Dropulić B, Lin NH, Jeang KT.

Nucleic Acids Res. 1993 May 11;21(9):2273-4. No abstract available.


Ribozymes: use as anti-HIV therapeutic molecules.

Dropulic B, Elkins DA, Rossi JJ, Sarver N.

Antisense Res Dev. 1993 Spring;3(1):87-94. No abstract available.


Supplemental Content

Loading ...
Support Center